HomeCompareMRUS vs PLD

MRUS vs PLD: Dividend Comparison 2026

MRUS yields 2.22% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $5.89M in total portfolio value
10 years
MRUS
MRUS
● Live price
2.22%
Share price
$90.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.0K
Annual income
$256.54
Full MRUS calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — MRUS vs PLD

📍 PLD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMRUSPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MRUS + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MRUS pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MRUS
Annual income on $10K today (after 15% tax)
$188.89/yr
After 10yr DRIP, annual income (after tax)
$218.06/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $4,037,898.35/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MRUS + PLD for your $10,000?

MRUS: 50%PLD: 50%
100% PLD50/50100% MRUS
Portfolio after 10yr
$2.97M
Annual income
$2,375,490.86/yr
Blended yield
80.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

MRUS
Analyst Ratings
10
Buy
12
Hold
Consensus: Hold
Price Target
$97.00
+7.8% upside vs current
Range: $97.00 — $97.00
Altman Z
34.5
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MRUS buys
0
PLD buys
0
No recent congressional trades found for MRUS or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMRUSPLD
Forward yield2.22%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$23.0K$5.91M
Annual income after 10y$256.54$4,750,725.19
Total dividends collected$2.4K$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$97.00$136.00

Year-by-year: MRUS vs PLD ($10,000, DRIP)

YearMRUS PortfolioMRUS Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$10,922$222.22$11,241$540.96$319.00PLD
2$11,914$226.84$13,019$991.13$1.1KPLD
3$12,979$231.24$15,801$1,870.97$2.8KPLD
4$14,123$235.43$20,609$3,701.21$6.5KPLD
5$15,351$239.43$29,919$7,867.97$14.6KPLD
6$16,669$243.22$50,631$18,617.74$34.0KPLD
7$18,082$246.82$105,528$51,352.20$87.4KPLD
8$19,598$250.24$287,364$174,449.42$267.8KPLD
9$21,224$253.47$1,081,760$774,280.77$1.06MPLD
10$22,966$256.54$5,908,209$4,750,725.19$5.89MPLD

MRUS vs PLD: Complete Analysis 2026

MRUSStock

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Full MRUS Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this MRUS vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MRUS vs SCHDMRUS vs JEPIMRUS vs OMRUS vs KOMRUS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.